VKTX Q3 Earnings Miss Estimates Amid Rising Clinical Expenses

VKTX posted a Q3 2026 loss of $1.55 per share as R&D spending jumped 85.4% to $166.8 million. The headline calls it a miss, though the article text says the loss "exceeded" expectations, which for a loss figure means a wider shortfall than analysts modeled.

The spending reflects a widening development push. VK2735, the company's lead obesity candidate, remains on track, with phase III studies expected to conclude in 2027 and a potential launch roughly 2.5 years away. Viking also initiated phase III trials for an oral formulation of VK2735 and expanded its pipeline with VK3019.

The balance sheet cushions the burn. VKTX holds $960 million in cash, which supports continued development through the phase III programs. Interpretation: with a launch still about 2.5 years out and no product revenue cited, the R&D line is the number that drives the loss, and the cash balance determines how long the company can fund it before outside capital becomes a question.

Interpretation only: an 85.4% jump in R&D in a single year signals that the phase III injectable and oral programs are now running concurrently, which likely keeps quarterly losses elevated through the 2027 readouts.